An experimental cancer medicine called larotrectinib has shown promise treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States. The treatment targets a genetic abnormality which is often found in rare cancers—including salivary gland cancer, juvenile breast cancer, and a soft tissue cancer known as infantile fibrosarcoma—which are...